Home › NCT04332341

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
* Subject must meet program eligibility criteria\* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
* HLA-identical related donor or unrelated human donor source with bone marrow graft.
* Subjects must provide a written informed consent.

Exclusion Criteria:

* History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
* Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
* Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.

About the study

The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.

What is being tested

• Nicotinamide riboside (NR) (drug)

Sponsor: Case Comprehensive Cancer Center · Participants: 20 · Started: May 19, 2020

Contact the study team

• Ronald Sobecks, MD · Phone: 1-866-223-8100

Official record on ClinicalTrials.gov — NCT04332341

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.